产品号 #72262_C
Retinoid pathway activator; Activates retinoic acid receptor (RAR)
概述
All-Trans Retinoic Acid is a derivative of Vitamin A that functions as a ligand for the retinoic acid receptor (RAR, IC₅₀ = 14 nM). RARs heterodimerize with retinoid X receptors (RXRs) and bind to retinoic acid response elements (RAREs) in DNA and act as transcription factors, altering gene expression. (Apfel et al., Chambon)
DIFFERENTIATION
· Promotes differentiation of motor neurons from mouse and human pluripotent stem cells (Dimos et al., Wichterle et al.).
· Promotes differentiation of neurons from neural stem cells (Takahashi et al.).
· Promotes differentiation of pancreatic progenitors from human embryonic stem (ES) cells (D'Amour et al.).
· Promotes differentiation of adipocytes from mouse ES cells (Dani et al.).
· Promotes differentiation of ventricular cardiomyocytes from mouse ES cells (Wobus et al.).
· Promotes terminal differentiation of granulocytes (Collins).
CANCER RESEARCH
· Promotes maturation of blast cells in differentiation therapy of acute promyelocytic leukemia (Huang et al.).
Cell Type
Adipocytes, Cardiomyocytes, PSC-Derived, Endoderm, PSC-Derived, Granulocytes and Subsets, Leukemia/Lymphoma Cells, Mesoderm, PSC-Derived, Neural Cells, PSC-Derived, Neurons, Pancreatic Cells, Pluripotent Stem Cells
Species
Human, Mouse, Non-Human Primate, Other, Rat
Application
Differentiation
Area of Interest
Cancer, Neuroscience, Stem Cell Biology
CAS Number
302-79-4
Chemical Formula
C₂₀H₂₈O₂
Purity
≥ 98%
Pathway
Retinoid
Target
RAR
Protocols and Documentation
Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.
Applications
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Resources and Publications
Educational Materials (5)
Publications (10)
Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science (New York, N.Y.) 2008 AUG
Abstract
The generation of pluripotent stem cells from an individual patient would enable the large-scale production of the cell types affected by that patient's disease. These cells could in turn be used for disease modeling, drug discovery, and eventually autologous cell replacement therapies. Although recent studies have demonstrated the reprogramming of human fibroblasts to a pluripotent state, it remains unclear whether these induced pluripotent stem (iPS) cells can be produced directly from elderly patients with chronic disease. We have generated iPS cells from an 82-year-old woman diagnosed with a familial form of amyotrophic lateral sclerosis (ALS). These patient-specific iPS cells possess properties of embryonic stem cells and were successfully directed to differentiate into motor neurons, the cell type destroyed in ALS.
Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nature biotechnology 2006 NOV
Abstract
Of paramount importance for the development of cell therapies to treat diabetes is the production of sufficient numbers of pancreatic endocrine cells that function similarly to primary islets. We have developed a differentiation process that converts human embryonic stem (hES) cells to endocrine cells capable of synthesizing the pancreatic hormones insulin, glucagon, somatostatin, pancreatic polypeptide and ghrelin. This process mimics in vivo pancreatic organogenesis by directing cells through stages resembling definitive endoderm, gut-tube endoderm, pancreatic endoderm and endocrine precursor--en route to cells that express endocrine hormones. The hES cell-derived insulin-expressing cells have an insulin content approaching that of adult islets. Similar to fetal beta-cells, they release C-peptide in response to multiple secretory stimuli, but only minimally to glucose. Production of these hES cell-derived endocrine cells may represent a critical step in the development of a renewable source of cells for diabetes cell therapy.
The role of retinoids and retinoic acid receptors in normal hematopoiesis. Leukemia 2002 OCT
Abstract
The dramatic therapeutic activity of all-trans retinoic acid (ATRA) in inducing terminal granulocytic differentiation of the malignant promyelocytes that characterize human acute promyelocytic leukemia (APL) has led to numerous studies assessing the role of retinoids and the retinoic acid receptors (RARs) in the regulation of normal hematopoiesis. Studies with knock out mice indicate that retinoic acid receptor activity is not essential for normal hematopoiesis, but both in vitro and in vivo studies indicate that these receptors may be important modifiers/regulators of different myeloid precursors/ progenitors including the primitive transplantable stem cell. A number of target genes have been identified that are either directly or indirectly regulated by RA receptors and which likely play important roles in the retinoid-mediated regulation of myelopoiesis. Several in vitro models of hematopoiesis suggest that the transcriptional activity of RA receptors is developmentally regulated during different stages of myelopoiesis. This regulation might involve non-ligand mediated molecular events that alter the interaction of RA receptors with transcriptional corepressor complexes. Moreover, the interaction of RA receptors with other families of transcription factors expressed in different hematopoietic lineages might also account for differential RA receptor activity at different stages of myelopoiesis.
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE. Safety Statement: CA WARNING: This product can expose you to All-trans Retinoic Acid which is known to the State of California to cause birth defects or other reproductive harm. For more information go to www.P65Warnings.ca.gov
